Literature DB >> 8784474

Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers.

I Takanami1, F Tanana, T Hashizume, K Kikuchi, Y Yamamoto, T Yamamoto, S Kodaira.   

Abstract

The expression of hepatocyte growth factor (HGF) and its receptor, c-Met, was investigated immunohistologically in tissue specimens of patients with a pulmonary adenocarcinoma. The prognosis was significantly worse in the HGF-positive or c-Met-positive patients than in the negative patients. Multivariate analysis showed that c-Met had a significant effect on the prognosis, whereas HGF did not. Our findings suggest that HGF and c-Met play an important role in tumor progression and that c-Met can be a useful prognostic marker for pulmonary adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784474     DOI: 10.1159/000227594

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  29 in total

1.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 3.  Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Authors:  Giovanna Finocchiaro; Luca Toschi; Letizia Gianoncelli; Marina Baretti; Armando Santoro
Journal:  Ann Transl Med       Date:  2015-04

Review 4.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

5.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

6.  Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.

Authors:  Xian-Zeng Hou; Wei Liu; Hai-Tao Fan; Bin Liu; Bo Pang; Tao Xin; Shang-Chen Xu; Qi Pang
Journal:  Neuro Oncol       Date:  2010-03-03       Impact factor: 12.300

7.  Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.

Authors:  Roya Navab; Jiang Liu; Isolde Seiden-Long; Warren Shih; Ming Li; Bizhan Bandarchi; Yan Chen; Davina Lau; Yen-Fen Zu; Dave Cescon; Chang Qi Zhu; Shawna Organ; Emin Ibrahimov; Dina Ohanessian; Ming-Sound Tsao
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 8.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

9.  Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.

Authors:  M I Galleges Ruiz; K Floor; S M Steinberg; K Grünberg; F B J M Thunnissen; J A M Belien; G A Meijer; G J Peters; E F Smit; J A Rodriguez; G Giaccone
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

Review 10.  New targets in non-small cell lung cancer.

Authors:  Shirish M Gadgeel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.